S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent adult Hodgkin lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed Hodgkin's lymphoma Relapsed or refractory disease Biopsy or radiological evidence of disease at time of recurrence/progression required Has received ≥ 1 prior systemic chemotherapy regimen No clonal abnormalities in marrow collection Must undergo involved-field radiotherapy if bulky disease > 5 cm Must have adequate sections of original diagnostic specimen available for review Needle aspirations or cytologies are not adequate No prior lymphoma, myelodysplastic syndromes, or leukemia (even if disease free > 5 years) Patients who relapse after achieving a complete remission must complete a minimum of 2 courses of salvage chemotherapy or radiation therapy to determine if sensitive or resistant recurrent disease is present No central nervous system (CNS) involvement PATIENT CHARACTERISTICS: Age 15 to 70 Performance status Zubrod 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Hodgkin's disease) Renal Creatinine clearance ≥ 60 mL/min Creatinine ≤ 2 times upper limit of normal Cardiovascular None of the following conditions requiring therapy: Coronary artery disease Cardiomyopathy Congestive heart failure Arrhythmias Ejection fraction ≥ 45% by Multi Gated Acquisition Scan (MUGA) or 2-D echocardiogram Pulmonary Adequate pulmonary function Corrected diffusing capacity of lung for carbon monoxide (DLCO) ≥ 60% OR Forced Expiratory Volume in One Side (FEV_1) ≥ 60% of predicted Other Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer No known HIV or AIDS infection No active bacterial, fungal, or viral infection No medical condition that would preclude study treatment PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy See Disease Characteristics Endocrine therapy Not specified Radiotherapy See Disease Characteristics Surgery Not specified
Sites / Locations
- University of California Davis Cancer Center
- Mountain States Tumor Institute at St. Luke's Regional Medical Center
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
- Cancer Center of Kansas, PA - Chanute
- Cancer Center of Kansas, PA - Dodge City
- Cancer Center of Kansas, PA - El Dorado
- Cancer Center of Kansas-Independence
- Cancer Center of Kansas, PA - Kingman
- Southwest Medical Center
- Cancer Center of Kansas, PA - Newton
- Cancer Center of Kansas, PA - Parsons
- Cancer Center of Kansas, PA - Pratt
- Cancer Center of Kansas, PA - Salina
- Cancer Center of Kansas, PA - Wellington
- Associates in Womens Health, PA - North Review
- Cancer Center of Kansas, PA - Medical Arts Tower
- Cancer Center of Kansas, PA - Wichita
- CCOP - Wichita
- Via Christi Cancer Center at Via Christi Regional Medical Center
- Cancer Center of Kansas, PA - Winfield
- Tulane Cancer Center Office of Clinical Research
- Legacy Mount Hood Medical Center
- Providence Milwaukie Hospital
- Legacy Good Samaritan Hospital & Comprehensive Cancer Center
- Providence Cancer Center at Providence Portland Medical Center
- Adventist Medical Center
- CCOP - Columbia River Oncology Program
- Providence St. Vincent Medical Center
- Legacy Emanuel Hospital and Health Center and Children's Hospital
- Legacy Meridian Park Hospital
- Thompson Cancer Survival Center
- Auburn Regional Center for Cancer Care
- St. Joseph Cancer Center
- Olympic Hematology and Oncology
- Providence Centralia Hospital
- St. Francis Hospital
- Columbia Basin Hematology
- Providence St. Peter Hospital Regional Cancer Center
- Good Samaritan Cancer Center
- Fred Hutchinson Cancer Research Center
- Harborview Medical Center
- Minor and James Medical, PLLC
- Group Health Central Hospital
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
- Polyclinic First Hill
- University Cancer Center at University of Washington Medical Center
- Cancer Care Northwest - Spokane South
- Franciscan Cancer Center at St. Joseph Medical Center
- Allenmore Hospital
- CCOP - Northwest
- MultiCare Regional Cancer Center at Tacoma General Hospital
- St. Clare Hospital
- Southwest Washington Medical Center Cancer Center
Arms of the Study
Arm 1
Experimental
High-dose therapy plus tandem transplant
Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.